External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Infectious Disease Hepatitis C

Hepatitis C

What's new

Sign up or login to unlock the full suite of MEDICALLY features
Oct 1 / Roche
Performance comparison of cobas e 801, Alinity s, and Alinity i serological screening parameters
Single-centre study evaluating the diagnostic performance of the Elecsys® infectious disease immunoassays on the cobas e 801 analytical unit of cobas® pro integrated solutions (all Roche Diagnostics International Ltd, Rotkreuz, Switzerland) for the detection of hepatitis B virus, hepatitis C virus, human immunodeficiency virus, syphilis, Chagas and human T-lymphotropic virus, versus commercially available immunoassays used in routine screening. Specificities were calculated for the Elecsys infectious disease immunoassays on the cobas 801 analytical unit and compared with the specificities of the respective immunoassays on Alinity S or Alinity I analysers.
Infectious Disease Acquired immune deficiency syndrome Hepatitis B Hepatitis C ISBT-2022

Sign up or login to unlock the full suite of MEDICALLY features
Oct 1 / Roche
Cobas MPX performance equivalency between the cobas 5800 system and cobas 6800/8800 systems
Study demonstrating the specificity of the cobas MPX test on the cobas 5800 System, and the equivalent sensitivity of the cobas MPX test on the cobas 5800 and on the cobas 6800/8800 Systems.
Infectious Disease Acquired immune deficiency syndrome Hepatitis B Hepatitis C ISBT-2022

Sign up or login to unlock the full suite of MEDICALLY features
Oct 1 / Roche
Video: Performance comparison of cobas e 801, Alinity s, and Alinity i serological screening parameters
Single-centre study evaluating the diagnostic performance of the Elecsys® infectious disease immunoassays on the cobas e 801 analytical unit of cobas® pro integrated solutions (all Roche Diagnostics International Ltd, Rotkreuz, Switzerland) for the detection of hepatitis B virus, hepatitis C virus, human immunodeficiency virus, syphilis, Chagas and human T-lymphotropic virus, versus commercially available immunoassays used in routine screening. Specificities were calculated for the Elecsys infectious disease immunoassays on the cobas 801 analytical unit and compared with the specificities of the respective immunoassays on Alinity S or Alinity I analysers.
Infectious Disease Acquired immune deficiency syndrome Hepatitis B Hepatitis C ISBT-2022

Sign up or login to unlock the full suite of MEDICALLY features
Oct 1 / Roche
Video: Cobas MPX performance equivalency between the cobas 5800 system and cobas 6800/8800 systems
Study demonstrating the specificity of the cobas MPX test on the cobas 5800 System, and the equivalent sensitivity of the cobas MPX test on the cobas 5800 and on the cobas 6800/8800 Systems.
Infectious Disease Acquired immune deficiency syndrome Hepatitis B Hepatitis C ISBT-2022

Sign up or login to unlock the full suite of MEDICALLY features
Sep 22 / Roche
Performance of the cobas e 601 serology platform for screening of donor blood for transfusion-transmissible infections in Uganda Blood Transfusion Service
The Uganda Blood Transfusion Service (UBTS) screens approximately 300,000 blood units for transfusion-transmissible infections annually. In this study, the authors comparatively evaluated the performance of the cobas® e 601 serology platform (Roche Diagnostics International Ltd) and the Architect i2000/Fortress/Immucor NEO algorithm, which is used at UBTS for routine donor blood screening. cobas e 601 showed a slightly better performance than Architect i2000 for HIV and HBsAg assays, and it provided fewer false reactive results in the HCV assay. For the syphilis assay, cobas e 601 also showed a higher relative specificity and sensitivity than NEO. These results indicate the potential utility of cobas e 601 for blood donor screening in UBTS.
Infectious Disease Acquired immune deficiency syndrome Hepatitis B Hepatitis C Syphilis AFSBT-2022

Sign up or login to unlock the full suite of MEDICALLY features
Jul 11 / Roche
Video: Multicentre performance evaluation of the Elecsys HCV Duo immunoassay
This international, multicentre study evaluated the diagnostic accuracy of the Elecsys HCV Duo immunoassay (Roche Diagnostics GmbH) on the cobas e 801 analyser (Roche Diagnostics International Ltd) for the detection of hepatitis C virus infection versus commercially available comparator assays. Specificity and sensitivity analyses were conducted for the Elecsys HCV Duo immunoassay, and the diagnostic window was evaluated versus polymerase chain reaction testing.
Infectious Disease Hepatitis C EASL-2022
Upcoming Congress
Access to Roche and Genentech's latest medical information
View related congresses

Ask a question or share feedback

Get in touch

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.